var data={"title":"Olanzapine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Olanzapine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6676?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">see &quot;Olanzapine: Drug information&quot;</a> and <a href=\"topic.htm?path=olanzapine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Olanzapine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537504\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709177\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration, 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5%, compared with a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patient is not clear. Olanzapine is not approved for treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Postinjection delirium/sedation syndrome (Zyprexa Relprevv): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Adverse reactions with signs and symptoms consistent with olanzapine overdose, in particular, sedation (including coma) and/or delirium, have been reported following injections of olanzapine extended release (ER). Olanzapine ER must be administered in a registered health care facility with ready access to emergency response services. After each injection, patients must be observed at the health care facility by a health care provider for at least 3 hours. Because of this risk, olanzapine ER is available only through a restricted distribution program called Zyprexa Relprevv Patient Care Program, and requires health care provider, health care facility, patient, and pharmacy enrollment.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26715078\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ZyPREXA;</li>\n      <li>ZyPREXA Relprevv;</li>\n      <li>ZyPREXA Zydis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203157\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Olanzapine;</li>\n      <li>ACT Olanzapine ODT;</li>\n      <li>Apo-Olanzapine;</li>\n      <li>Apo-Olanzapine ODT;</li>\n      <li>Auro-Olanzapine ODT;</li>\n      <li>JAMP Olanzapine FC;</li>\n      <li>JAMP-Olanzapine ODT;</li>\n      <li>Mar-Olanzapine;</li>\n      <li>Mar-Olanzapine ODT;</li>\n      <li>Mint-Olanzapine ODT;</li>\n      <li>Mylan-Olanzapine;</li>\n      <li>Mylan-Olanzapine ODT;</li>\n      <li>Olanzapine for injection;</li>\n      <li>Olanzapine ODT;</li>\n      <li>PHL-Olanzapine;</li>\n      <li>PHL-Olanzapine ODT;</li>\n      <li>PMS-Olanzapine;</li>\n      <li>PMS-Olanzapine ODT;</li>\n      <li>RAN-Olanzapine;</li>\n      <li>RAN-Olanzapine ODT;</li>\n      <li>Riva-Olanzapine;</li>\n      <li>Riva-Olanzapine ODT;</li>\n      <li>Sandoz-Olanzapine;</li>\n      <li>Sandoz-Olanzapine ODT;</li>\n      <li>Teva-Olanzapine;</li>\n      <li>Teva-Olanzapine ODT;</li>\n      <li>Van-Olanzapine;</li>\n      <li>Zyprexa;</li>\n      <li>Zyprexa Intramuscular;</li>\n      <li>Zyprexa Zydis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028249\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Second Generation (Atypical) Antipsychotic </span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028285\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">see &quot;Olanzapine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Bipolar I disorder</b> (acute manic or mixed episodes): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to &lt;6 years: Limited data available: Initial: 1.25 mg once daily; increase at weekly intervals according to response and tolerability to target dose: 10 mg/day.  Dosing based on an open-label trial in 15 children (mean age: 5 &plusmn; 0.8 years; mean weight: 20.8 kg; mean required dose: 6.3 &plusmn; 2.3 mg/day) that showed significant improvement in manic symptoms (Biederman, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6-12 years: Limited data available: Initial: 2.5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day (Frazier, 2001; Kowatch, 2006; Wozniak, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:  Initial: 2.5-5 mg once daily;  increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day. In adolescent flexible-dosing (2.5-20 mg/day) clinical trials, the mean modal dose was 10.7 mg/day (mean dose: 8.9 mg/day) (Kowatch, 2006; Tohen, 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Schizophrenia:</b> Children &ge;8 years (Limited data available) and Adolescents: Initial: 2.5-5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day. <b>Note:</b> Doses up to 30 mg/day were used in one study of adolescents who were treatment refractory; however, some patients did not tolerate doses &gt; 20 mg/day (Kumra, 2008); safety and efficacy of doses &gt;20 mg/day have not been fully evaluated. In adolescent flexible-dosing (2.5-20 mg/day) clinical trials, the mean modal dose was 12.5 mg/day (mean dose: 11.1 mg/day). Dosing in children is based on two double-blind comparison studies which included both children and adolescents [n=35, age: 8-19 years with seven children; n=13, age: 7-16 years (mean age: 12.8 + 2.4 years)] (Shaw, 2006; Sikich, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Anorexia nervosa:</b> Children &ge;9 years and Adolescents: Limited data available: 1.25-2.5 mg once daily has been shown in one small trial and several case reports to improve BMI and other disease-related symptoms (eg, eating attitudes, anxiety); another case series used initial doses of 2.5 mg once daily and final doses of 5 mg to 10 mg once daily; reported range: 1.25-12.5 mg/day; however, it has been suggested that higher doses (&gt;2.5 mg once daily) may not be associated with greater efficacy (Boachie, 2003; Dunican, 2007; Legerro, 2010; Mehler, 2001; Mehler-Wex, 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Tourette syndrome, tic disorder:</b> Children &ge;7 years and Adolescents: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &le;40 kg: Initial: 2.5 mg every other day for 3 days, increase to 2.5 mg every day for remainder of week; increase to 5 mg/day by second week if needed; then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &gt;40 kg: Initial: 2.5 mg every day for 3 days; increase to 5 mg every day for remainder of week if needed, then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">An open-label study of 10 pediatric patients (7-13 years of age) reported significant reductions in tic severity [Yale Global Tic Severity Scale (YGTSS)] from baseline at a mean final dose of 14.5 mg/day after 8 weeks of treatment (Stephens, 2004). An open-label trial of 12 children and adolescents (7-14 years of age) reported a significant reduction (30%) in total tic severity (YGTSS) at a final mean dose of 11.3 mg/day (range: 2.5-20 mg/day) (McCracken, 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Acute mania associated with bipolar disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Monotherapy: Initial: 10-15 mg once daily; increase by 5 mg/day at intervals of not less than 24 hours. Maintenance: 5-20 mg/day; recommended maximum dose: 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Combination therapy (with lithium or valproate): Initial: 10 mg once daily; dosing range: 5-20 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Schizophrenia:</b> Initial: 5-10 mg once daily (increase to 10 mg once daily within 5-7 days); thereafter, adjust by 5 mg/day at 1-week intervals, up to a recommended maximum of 20 mg/day. Maintenance: 10-20 mg once daily. Doses of 30-50 mg/day have been used; however, doses &gt;10 mg/day have not demonstrated better efficacy, and safety and efficacy of doses &gt;20 mg/day have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM (short-acting): <b>Agitation</b> (acute, associated with bipolar disorder or schizophrenia): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients: Limited data available: Children: 5 mg; Adolescents: 10 mg. Dosing based on a retrospective report of IM olanzapine use in an inpatient psychiatric setting which included 50 pediatric patients [children (n=15; mean age: 11 years); adolescents (n=35; mean age: 15 years)] and evaluated 163 doses administered; results showed a 90.2% response rate (Khan, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Initial dose: 10 mg (a lower dose of 5-7.5 mg may be considered when clinical factors warrant); additional doses (up to 10 mg) may be considered; however, 2-4 hours should be allowed between doses to evaluate response (maximum total daily dose: 30 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM (extended release): Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia:</b> <b>Note:</b> Establish tolerance to oral olanzapine prior to changing to extended release IM injection. It may take up to 3 months to re-establish steady-state when switching from oral olanzapine to long-acting IM injection. Maximum dose: 300 mg/2 weeks or 405 mg/4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients established on oral olanzapine 10 mg/day: Initial dose: 210 mg every 2 weeks for 4 doses or 405 mg every 4 weeks for 2 doses; Maintenance dose: 150 mg every 2 weeks or 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients established on oral olanzapine 15 mg/day: Initial dose: 300 mg every 2 weeks for 4 doses; Maintenance dose: 210 mg every 2 weeks or 405 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients established on oral olanzapine 20 mg/day: Initial and maintenance dose: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients who are debilitated, predisposed to hypotensive reactions, exhibit multiple factors that may result in slower metabolism, or may be more sensitive to olanzapine: Initial dose: 150 mg every 4 weeks; increase dose with caution and only if clinically needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> No dosage adjustment required. Not removed by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Use with caution. Dosage adjustment may be necessary; however, no specific recommendations exist. Monitor closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26715079\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 10 mg (1 ea) [contains tartaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA Relprevv: 210 mg (1 ea); 300 mg (1 ea); 405 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 2.5 mg, 5 mg, 7.5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 15 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA Zydis: 5 mg, 10 mg, 15 mg, 20 mg [contains aspartame, methylparaben sodium, propylparaben sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26730983\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874938\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zyprexa and Zyprexa Zydis: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQRbJoH1bIwPN4EPbLUaSXXg==&amp;TOPIC_ID=16033\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zyprexa Relprevv: http://pi.lilly.com/us/zyprexa_relprevv.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028292\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablet: May be administered with or without food. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orally disintegrating tablet: Remove from foil blister by peeling back foil (do not push tablet through the foil); place tablet in mouth immediately upon removal; tablet dissolves rapidly in saliva and may be swallowed with or without liquid. May be administered with or without food/meals.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM (short-acting): For IM administration only; do not administer IV or subcutaneously; inject slowly, deep into muscle mass. If dizziness and/or drowsiness are noted, patient should remain recumbent until examination indicates postural hypotension and/or bradycardia are not a problem.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">  IM (extended release): Adults: For deep IM gluteal administration only; do not administer injection intravenously. After needle insertion into muscle, aspirate to verify that no blood appears; inject slowly, deep into muscle. Do not massage injection site. Use diluent, syringes, and needles provided in convenience kit; obtain a new kit if aspiration of blood occurs. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203151\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, extended-release: Store at controlled room temperature, not to exceed 30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, short-acting: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet and orally disintegrating tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028250\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of schizophrenia (FDA approved in ages &ge;13 years and adults); acute and maintenance treatment of manic or mixed episodes of bipolar I disorder (FDA approved in ages &ge;13 years and adults); adjunctive therapy (to lithium or valproate) for treatment of manic or mixed episodes of bipolar I disorder (FDA approved in adults); in combination with fluoxetine for treatment-resistant depression or depressive episodes associated with bipolar I disorder (FDA approved in adults). Has also been used for anorexia nervosa, autism spectrum disorders, Tourette syndrome, and tic disorders. Therapy should only be initiated in pediatric patients after a thorough diagnostic evaluation and an assessment of potential long-term risks; adolescent patients experience a higher incidence of weight gain, and greater increases in total cholesterol, triglycerides, LDL, prolactin, and hepatic transaminase concentrations than adult patients; other agents with fewer risks may be preferred as first-line treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM extended release (Zyprexa&reg; Relprevv&trade;): Treatment of schizophrenia (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM short-acting (Zyprexa&reg; IntraMuscular): Treatment of acute agitation associated with schizophrenia and bipolar I mania (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203206\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">OLANZapine may be confused with olsalazine, QUEtiapine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZyPREXA may be confused with CeleXA, Reprexain, Zestril, ZyrTEC</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZyPREXA Zydis may be confused with Zelapar, zolpidem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZyPREXA Relprevv may be confused with ZyPREXA IntraMuscular</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. Antipsychotics like olanzapine may have anticholinergic properties. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203203\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, hypertension, orthostatic hypotension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal gait, akathisia, articulation impairment, dizziness (more common in adults), drowsiness (dose dependent), extrapyramidal reaction (dose dependent; more common in adults), falling, fatigue (dose dependent), headache, hypertonia, insomnia, parkinsonian-like syndrome (includes akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, maked facies, and tremor), personality disorder, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Breast changes (including discharge, enlargement, galactorrhea, gynecomastia, lactation disorder), increased gamma-glutamyl transferase, increased serum prolactin (more common in adolescents), increased uric acid, menstrual disease (including amenorrhea, hypomenorrhea, delayed menstruation, oligomenorrhea), weight gain (more common in adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (adolescents), constipation, diarrhea (adolescents), dyspepsia (more common in adults), increased appetite (more common in adolescents), vomiting, xerostomia (dose dependent; more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Sexual disorder (less common in adolescents; anorgasmia, delayed ejaculation, erectile dysfunction, changes in libido, abnormal orgasm, sexual dysfunction), urinary incontinence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Decreased serum bilirubin, increased liver enzymes, increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (more common in adults), back pain, dyskinesia, limb pain, muscle rigidity (adolescents), tremor (dose dependent), weakness (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Amblyopia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, epistaxis, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Injection:</b> Unless otherwise noted, adverse events are reported for placebo-controlled trials in adult patients on extended release IM injection (Zyprexa Relprevv). Also refer to adverse reactions noted with oral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension, hypotension, prolonged Q-T interval on ECG, orthostatic hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal dreams, abnormality in thinking, akathisia, auditory hallucination, dizziness, drowsiness, dysarthria, extrapyramidal reaction, fatigue, headache, pain, parkinsonian-like syndrome, procedural pain, restlessness, sleep disorder, sedation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, diarrhea, flatulence, increased appetite, nausea (more common in long-acting IM formula), toothache, tooth infection, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal discharge</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Abscess at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle spasm, stiffness, tremor (more common in long-acting IM formula)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, sneezing, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal distension, accommodation disturbance, agranulocytosis, alopecia, anaphylactoid reaction, angioedema, ataxia, cerebrovascular accident, chills, coma, confusion, delirium, diabetes mellitus, diabetic ketoacidosis, diabetic coma, difficulty in micturition, DRESS syndrome, dry eye syndrome, dysarthria, facial edema, hangover effect, hepatic injury (cholestatic or mixed), hepatitis, hyperbilirubinemia, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypermenorrhea, hypertriglyceridemia, hypoproteinemia, impotence, increased creatine phosphokinase, intestinal obstruction, jaundice, ketosis, leukocytosis (eosinophilia), leukopenia, liver steatosis, mastalgia, mydriasis, myopathy, nausea, neuroleptic malignant syndrome, neutropenia, osteoporosis, pancreatitis, polyuria, postinjection delirium/sedation syndrome, priapism, pruritus, pulmonary edema, pulmonary embolism, respiratory depression (Cole 2007), restless legs syndrome, rhabdomyolysis, seizure, skin photosensitivity, skin rash, sleep apnea syndrome (obstructive) (Health Canada 2016; Shirani 2011), stupor, suicidal tendencies, syncope, tardive dyskinesia, thrombocytopenia, tongue edema, transient ischemic attacks, urinary frequency, urinary retention, urinary urgency, urticaria, vasodilation, venous thrombosis, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203138\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to olanzapine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203120\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems (including narrow-angle glaucoma). Relative to other neuroleptics, olanzapine has a moderate potency of cholinergic blockade (Richelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of olanzapine for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which impair physical and mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). May be moderate to highly sedating in comparison with other antipsychotics (APA [Lehman 2004]); dose-related effects have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Dose-related increases in cholesterol and triglycerides have been noted. Use with caution in patients with preexisting abnormal lipid profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Olanzapine may have a greater association with hyperglycemia than other atypical antipsychotics. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodic assessment of glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: May cause dose-related increases in prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown. Clinical manifestations of increased prolactin levels included menstrual-, sexual- and breast-related events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious, sometimes fatal, multiorgan hypersensitivity reactions (DRESS) have been reported. Symptoms may include a cutaneous reaction (rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications (eg, hepatitis, nephritis, pneumonitis, myocarditis, pericarditis). Discontinue olanzapine if DRESS is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use that may predispose to hypotension/bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain (&gt;7% of baseline weight) has been observed with antipsychotic therapy; incidence varies with product. Dose-related changes have been observed with olanzapine. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction, ischemic heart disease, or hypercholesterolemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared with placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death. (APA [Reus 2016]). Olanzapine is not approved for the treatment of dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; may increase transaminases (primarily ALT).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotic may aggravate motor disturbances (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications that may lower seizure threshold. Elderly patients may be at increased risk of seizures because of an increased prevalence of predisposing factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adolescents: Use in patients &ge;13 years of age may result in increased weight gain and sedation, as well as greater increases in LDL cholesterol, total cholesterol, triglycerides, prolactin, and liver transaminase levels when compared with adults. Adolescent patients should be maintained on the lowest dose necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smokers: Olanzapine levels may be lower in patients who smoke. Smokers may require a daily dose 30% higher than nonsmokers in order to obtain an equivalent olanzapine concentration (Tsuda 2014); however, the manufacturer does not routinely recommend dosage adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form-specific concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intramuscular formulations: There are two Zyprexa formulations for intramuscular injection: Zyprexa Relprevv is an extended-release formulation and Zyprexa IntraMuscular is short-acting.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended-release IM injection (Zyprexa Relprevv):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postinjection delirium/sedation syndrome: <b>[US Boxed Warning]: Sedation (including coma) and delirium (including agitation, anxiety, confusion, disorientation) have been observed following use of Zyprexa Relprevv;</b> events associated with an inadvertent rapid rise in serum concentrations; administer at a registered health care facility where patients should be continuously monitored (&ge;3 hours) for symptoms of olanzapine overdose; symptom development highest in first hour but may occur within or after 3 hours; risk of syndrome is cumulative with each injection; recovery expected by 72 hours. Upon determining alert status, patient should be escorted to their destination and not drive or operate heavy machinery for the remainder of the day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Unexplained deaths: Two unexplained deaths in patients who received <i>Zyprexa Relprevv</i> have been reported. The patients died 3 to 4 days after receiving an appropriate dose of the drug. Both patients were found to have high blood concentrations of olanzapine postmortem. It is unclear if these deaths were the result of postinjection delirium sedation syndrome (PDSS) (FDA Safety Communication 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Restricted distribution program: Zyprexa Relprevv is only available under a restricted distribution program. Only prescribers, health care facilities, and pharmacies registered with the program are able to prescribe, distribute, or dispense Zyprexa Relprevv for patients who are enrolled in and meet all conditions of the program.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Short-acting IM injection (Zyprexa IntraMuscular):</i> Patients should remain recumbent if drowsy/dizzy until hypotension, bradycardia, and/or hypoventilation have been ruled out. Closely monitor for orthostasis prior to any repeat dosing. Concurrent use of IM/IV benzodiazepines is not recommended (fatalities have been reported, though causality not determined).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: IV administration has only been studied in emergency department settings, where patients can be closely monitored for respiratory depression (ie, pulse oximetry) (Chan 2013; Cole 2017; Martel 2015; Taylor 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26019544\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder and schizophrenia is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A higher incidence of hyperprolactinemia has been observed in adolescent patients treated with olanzapine than adults (47% vs 30%), high concentrations of prolactin may reduce pituitary gonadotropin secretion; galactorrhea, amenorrhea, gynecomastia, impotence, decreased bone density may occur. Use with caution in children and adolescents as adverse effects due to elevated serum prolactin concentrations have been observed; long-term effects on growth or sexual maturation have not been evaluated. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In adolescent patients, increases in fasting total cholesterol, LDL cholesterol, and triglycerides were generally greater than in adult patients; measure fasting serum lipids at the beginning of therapy and periodically during therapy in these patients. Compared to adult patients, adolescent patients had both greater magnitude of weight gain and proportion of patients who had clinically significant weight gain (incidence: 29% to 40% vs 6%). With long-term olanzapine exposure (&ge;24 weeks), 89% of adolescents gained at least 7% of their baseline body weight, 55% gained at least 15% of their baseline body weight, and 29% gained at least 25% of their baseline body weight; discontinuation due to weight gain occurred in 2.2%. Monitor growth (including weight, height, BMI, and waist circumference) in pediatric and adolescent patients receiving olanzapine; compare weight gain to standard growth curves. <b>Note:</b> A prospective, nonrandomized, cohort study followed 338 antipsychotic naive pediatric patients (age: 4 to 19 years) for a median of 10.8 weeks (range: 10.5 to 11.2 weeks) and showed that olanzapine was associated with greater increases in weight, fat mass, BMI, and waist circumference than other atypical antipsychotics evaluated (ie, quetiapine, risperidone, and aripiprazole). The following significant mean increases in weight in kg (and % change from baseline) were reported: Olanzapine: 8.5 kg (15.2%), quetiapine: 6.1 kg (10.4%), risperidone: 5.3 kg (10.4%), and aripiprazole: 4.4 kg (8.1%) compared to the control cohort: 0.2 kg (0.65%). Also, compared to the other atypical antipsychotics evaluated, olanzapine showed higher increases in metabolic indices (eg, serum glucose, total cholesterol and LDL-C). Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested (Correll 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> Hyperglycemia has been reported with olanzapine; in analysis of pediatric trials (adolescents &ge;13 years), diagnosis including schizophrenia and bipolar disorder, olanzapine therapy was associated with a greater mean change in fasting glucose than placebo-treated patients (2.68 mg/dL vs -2.59 mg/dL).  However, with longer exposure (mean: 17.2 months), an increased risk for the development of type 2 diabetes mellitus (DM) was observed in pediatric patients 10 to 18 years receiving second-generation antipsychotics (SGA); for patients initiated on SGA: 0.4% incidence with mean exposure at time type 2 DM diagnosed: 13.5 months; for SGA noniniators (patients receiving another agent prior to SGA initiation): 0.2% incidence with mean exposure at time of type 2 DM diagnosed: 14.6 months. Amongst specific SGAs, the risk was highest for aripiprazole (p=0.001) followed by ziprasidone (p=0.06) compared to risperidone as the reference group but not quetiapine or olanzapine (Rubin 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Olanzapine is moderate to highly sedating; a higher frequency of sedation-related adverse events (defined as hypersomnia, lethargy, sedation, and somnolence) have been observed in adolescents compared to adults. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203191\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203125\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16033&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepines: OLANZapine may enhance the adverse/toxic effect of Benzodiazepines.  Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May enhance the sedative effect of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203127\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2839122\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Olanzapine crosses the placenta and can be detected in cord blood at birth (Newport 2007). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited, as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is needed in a woman planning a pregnancy or if treatment is initiated during pregnancy, olanzapine may be used (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Olanzapine may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to olanzapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028296\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs; CBC with differential, fasting lipid profile, and fasting blood glucose/Hgb A<sub>1c</sub> (prior to treatment, at 3 months, then annually or as symptoms warrant); periodic assessment of hepatic transaminases; weight, BMI, waist circumference; personal/family history of diabetes or obesity; orthostatic blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS). Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider switching to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. Monitor patient periodically for symptom resolution. Following IM administration, if dizziness and/or drowsiness are noted, patient should remain recumbent until resolved. Extended release IM injection (Zyprexa&reg; Relprevv&trade;): Monitor patients continuously for 3 hours after injection for symptoms of postinjection sedation syndrome and olanzapine overdose; once patient is alert, escort patient to their destination; patient should not drive or operate heavy machinery for the remainder of the day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203119\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Olanzapine is a second generation thienobenzodiazepine antipsychotic which displays potent antagonism of serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub>, dopamine D<sub>1-4</sub>, histamine H<sub>1</sub>, and alpha<sub>1</sub>-adrenergic receptors. Olanzapine shows moderate antagonism of 5-HT<sub>3</sub> and  muscarinic M<sub>1-5 </sub>receptors, and weak binding to GABA-A, BZD, and beta-adrenergic receptors. Although the precise mechanism of action in schizophrenia and bipolar disorder is not known, the efficacy of olanzapine is thought to be mediated through combined antagonism of dopamine and serotonin type 2 receptor sites. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203137\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within 1 to 2 weeks for control of aggression, agitation, insomnia; 3 to 6 weeks for control of mania and positive psychotic symptoms. Adequate trial: Typically 6 weeks at maximum tolerated doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Well absorbed; not affected by food; tablets and orally disintegrating tablets are bioequivalent</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Short-acting injection: Rapidly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Extensive, 1,000 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 93% bound to albumin and alpha<sub>1</sub>-glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Highly metabolized via direct glucuronidation and cytochrome P450 mediated oxidation (CYP1A2, CYP2D6); 40% removed via first pass metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral and IM (short-acting): Children: (10 to 18 years; n=8): 37.2 &plusmn; 5.1 hours (Grothe 2000); Adults: 30 hours [21 to 54 hours (5th to 95th percentile)]; approximately 1.5 times greater in elderly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release injection: ~30 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Maximum plasma concentrations after IM administration are 5 times higher than maximum plasma concentrations produced by an oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release injection: ~7 day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Short-acting injection: 15 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Children (10 to 18 years; n=8): 4.7 &plusmn; 3.7 hours (Grothe 2000); Adults: ~6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (57%, 7% as unchanged drug); feces (30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children (10 to 18 years; n=8): Apparent: 9.6 &plusmn; 2.4 L/hour (Grothe 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: Apparent: 25 L/hour [12 to 47 L/hour (5th to 95th percentile)]; 40% increase in olanzapine clearance in smokers; 30% decrease in females</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11408495\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Long-term usefulness of olanzapine should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Additional detailed olanzapine dosing information for Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Autism spectrum disorders:</b> <b>Note:</b> Limited information exists in the literature; dose not established; efficacy results have been variable; further studies are needed. A double-blind, placebo-controlled study (n=11, 6-14 years of age, study duration: 8 weeks) reported a response in only 3 of 6 treatment arm patients using an initial dose of: 2.5 mg every other day (patient weight: &lt;40 kg) or 2.5 mg every day (patient weight: &ge;40 kg); dose increased at weekly intervals in 2.5-5 mg increments as tolerated (maximum dose allowed: 20 mg/day); final dosage range: 7.5-12.5 mg/day; mean: 10 mg/day (Hollander, 2006). An open-label, 6-week, comparative study with haloperidol in 12 children (4.8-11.8 years of age) used a similar dosing regimen and reported responses in 5 of 6 patients in the olanzapine treatment arm; final dosage range: 5-10 mg/day (mean: 7.9 &plusmn; 2.5 mg/day) (Malone, 2001). However, an open-label, 12-week study in 25 pediatric patients (6-16 years) reported a response in only three patients, final dosage range: 2.5-20 mg/day (mean: 10.7 mg/day) (Kemner, 2002). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203140\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (OLANZapine Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $41.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (ZyPREXA Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $51.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (ZyPREXA Relprevv Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">210 mg (1): $707.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $1,010.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">405 mg (1): $1,364.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (OLANZapine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $428.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $629.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $927.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,226.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (ZyPREXA Zydis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $17.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $25.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $37.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $49.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (OLANZapine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $335.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $396.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $481.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $596.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $895.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,193.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ZyPREXA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $410.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $484.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $589.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $729.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $1,094.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,459.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203142\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aedon (AT, CZ);</li>\n      <li>Arenbil (ES);</li>\n      <li>Benexafrina OD (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Benzopain (JO);</li>\n      <li>Dozic (CO, PY);</li>\n      <li>Egolanza (CZ, VN);</li>\n      <li>Exzapine (PH);</li>\n      <li>Lanzine (TZ);</li>\n      <li>Lapozan (LV);</li>\n      <li>Lopez (BD);</li>\n      <li>Marathon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Meflax (EC);</li>\n      <li>Midax (PY);</li>\n      <li>Nodoff (TW);</li>\n      <li>Nykob (CZ);</li>\n      <li>Okpine (TW);</li>\n      <li>Olan (LK);</li>\n      <li>Olandoz (ID);</li>\n      <li>Olankline (MY, SG);</li>\n      <li>Olanpin (KR);</li>\n      <li>Olanstad (VN);</li>\n      <li>Olanza (BD, HK, PH, TH);</li>\n      <li>Olanza OD (KR);</li>\n      <li>Olanzapro (PH);</li>\n      <li>Olapin-10 (KR, TH);</li>\n      <li>Olapine (BD);</li>\n      <li>Olazax (AT, IE);</li>\n      <li>Olazine (QA);</li>\n      <li>Oleanz (IN);</li>\n      <li>Olmed (VN);</li>\n      <li>Onzapin (HK, ID, SG);</li>\n      <li>Onzapin OD (HK);</li>\n      <li>Onzapin ODT (SG);</li>\n      <li>Ozapex (KR);</li>\n      <li>Ozin (AU);</li>\n      <li>Placet (PY, UY);</li>\n      <li>Prexal (JO, QA);</li>\n      <li>Remital (ID);</li>\n      <li>Rolyprexa (IE);</li>\n      <li>Tiantrex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tolanz (LK);</li>\n      <li>Tolaz MD (IN);</li>\n      <li>Torolan (VN);</li>\n      <li>Ximin (CN);</li>\n      <li>Xytrex (BD);</li>\n      <li>Zalasta (ES, IE, LV, MT, PL, UA);</li>\n      <li>Zanprex (PH);</li>\n      <li>Zapilux (BG);</li>\n      <li>Zapine (LK);</li>\n      <li>Zappa (IL);</li>\n      <li>Zelta (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Zeprex (PH);</li>\n      <li>Zolafren (ES, VN);</li>\n      <li>Zozapin (LK);</li>\n      <li>Zylap (AU);</li>\n      <li>Zypadhera (AT, DE, DK, EE, ES, FR, GB, HR, IE, IL, IS, LT, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>ZypAdhera (QA);</li>\n      <li>Zypeace OD (KR);</li>\n      <li>Zypine (AU);</li>\n      <li>Zypine ODT (AU);</li>\n      <li>Zypreksa (UA);</li>\n      <li>Zyprexa (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, ID, IE, IL, IS, IT, JO, JP, KE, KW, LB, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, TH, TN, TR, TW, TZ, UG, VE, VN, ZA, ZM, ZW);</li>\n      <li>Zyprexa Velotab (AE, AT, BE, BG, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, KW, LB, MT, NL, NO, PL, PT, QA, RU, SE, SK, TR);</li>\n      <li>Zyprexa Zydis (AR, BB, CN, HK, ID, MY, NZ, PH, SG, TH, TW);</li>\n      <li>Zyrepin (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo; <i>Diabetes Care</i>, 2004, 27(2):596-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/14747245/pubmed\" target=\"_blank\" id=\"14747245\">14747245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo; <i>Breastfeed Med</i>, 2007, 2(1):10-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17661614/pubmed\" target=\"_blank\" id=\"17661614\">17661614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biederman J, Mick E, Hammerness P, et al, &quot;Open-Label, 8-Week Trial of Olanzapine and Risperidone for the Treatment of Bipolar Disorder in Preschool-Age Children,&quot; <i>Biol Psychiatry</i>, 2005, 58(7):589-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/16239162/pubmed\" target=\"_blank\" id=\"16239162\">16239162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boachie A, Goldfield GS, and Spettigue W, &quot;Olanzapine Use as an Adjunctive Treatment for Hospitalized Children With Anorexia Nervosa: Case Reports,&quot; <i>Int J Eat Disord</i>, 2003, 33(1):98-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/12474205/pubmed\" target=\"_blank\" id=\"12474205\">12474205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23902726\"></a>Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. <i>BMC Pharmacol Toxicol</i>. 2013;14:38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/23902726/pubmed\" target=\"_blank\" id=\"23902726\">23902726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16529334\"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13 Suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carrillo JA, Herraiz AG, Ramos SI, et al, &quot;Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine,&quot; <i>J Clin Psychopharmacol</i>, 2003, 23(2):119-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/12640212/pubmed\" target=\"_blank\" id=\"12640212\">12640212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chavez B, Chavez-Brown M, Sopko MA Jr, et al, &quot;Atypical Antipsychotics in Children With Pervasive Developmental Disorders,&quot; <i>Paediatr Drugs</i>, 2007, 9(4):249-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17705564/pubmed\" target=\"_blank\" id=\"17705564\">17705564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23821039\"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Correll CU, Manu P, Olshanskiy V, et al, &quot;Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,&quot; <i>JAMA</i>, 2009, 302(16):1765-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/19861668/pubmed\" target=\"_blank\" id=\"19861668\">19861668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunican KC and DelDotto D, &quot;The Role of Olanzapine in the Treatment of Anorexia Nervosa,&quot; <i>Ann Pharmacother</i>, 2007, 41(1):111-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17190846/pubmed\" target=\"_blank\" id=\"17190846\">17190846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farwell WR, Stump TE, Wang J, et al, &quot;Weight Gain and New Onset Diabetes Associated With Olanzapine and Risperidone,&quot; <i>J Gen Intern Med</i>, 2004, 19(12):1200-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/15610330/pubmed\" target=\"_blank\" id=\"15610330\">15610330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frazier JA, Biederman J, Tohen M, et al, &quot; A Prospective Open-Label Treatment Trial of Olanzapine Monotherapy in Children and Adolescents With Bipolar Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2001, 11(3):239-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/11642474/pubmed\" target=\"_blank\" id=\"11642474\">11642474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ, Kristensen JH, Begg EJ, et al, &quot;Transfer of Olanzapine Into Breast Milk, Calculation of Infant Drug Dose, and Effect on Breast-Fed Infants,&quot; <i>Am J Psychiatry</i>, 2003, 160(8):1428-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/12900304/pubmed\" target=\"_blank\" id=\"12900304\">12900304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilad O, Merlob P, Stahl B, et al, &quot;Outcome of Infants Exposed to Olanzapine During Breastfeeding,&quot; <i>Breastfeed Med</i>, 2011, 6(2):55-8<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/21034242/pubmed\" target=\"_blank\" id=\"21034242\">21034242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein DJ, Corbin LA, and Fung MC, &quot;Olanzapine-Exposed Pregnancies and Lactation: Early Experience,&quot; <i>J Clin Psychopharmacol</i>, 2000, 20(4):399-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/10917399/pubmed\" target=\"_blank\" id=\"10917399\">10917399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grothe DR, Calis KA, Jacobsen L, et al, &quot;Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients With Childhood-Onset Schizophrenia,&quot; <i>J Clin Psychopharmacol</i>, 2000, 20(2):220-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/10770461/pubmed\" target=\"_blank\" id=\"10770461\">10770461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22834451\"></a>Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander E, Wasserman S, Swanson EN, et al, &quot;A Double-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive Developmental Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(5):541-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17069543/pubmed\" target=\"_blank\" id=\"17069543\">17069543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kemner C, Willemsen-Swinkels SH, de Jonge M, et al, &quot;Open-Label Study of Olanzapine in Children With Pervasive Developmental Disorder,&quot; <i>J Clin Psychopharmacol</i>, 2002, 22(5):455-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/12352267/pubmed\" target=\"_blank\" id=\"12352267\">12352267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan SS and Mican LM, &quot;A Naturalistic Evaluation of Intramuscular Ziprasidone Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Children and Adolescents,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(6):671-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17201611/pubmed\" target=\"_blank\" id=\"17201611\">17201611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kowatch RA, Fristad M, Birmaher B, et al, &quot;Treatment Guidelines for Children and Adolescents With Bipolar Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2005, 44(3):213-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/15725966/pubmed\" target=\"_blank\" id=\"15725966\">15725966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kryzhanovskaya L, Schulz SC, McDougle C, et al, &ldquo;Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatr</i>y, 2009, 48(1):60-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/19057413/pubmed\" target=\"_blank\" id=\"19057413\">19057413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumra S, Kranzler H, Gerbino-Rosen G, et al, &quot;Clozapine and 'HighDose' Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison,&quot; <i>Biol Psychiatry</i>, 2008, 63(5):524-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leggero C, Masi G, Brunori E, et al, &quot;Low-Dose Olanzapine Monotherapy in Girls With Anorexia Nervosa, Restricting Subtype: Focus on Hyperactivity,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2010, 20(2):127-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/20415608/pubmed\" target=\"_blank\" id=\"20415608\">20415608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15000267\"></a>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RP, Cater J, Sheikh RM, et al, &quot;Olanzapine Versus Haloperidol in Children With Autistic Disorder: An Open Pilot Study,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2001, 40(8):887-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/11501687/pubmed\" target=\"_blank\" id=\"11501687\">11501687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17195735\"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17195735/pubmed\" target=\"_blank\" id=\"17195735\">17195735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCracken JT, Suddath R, Chang S, et al, &quot;Effectiveness and Tolerability of Open Label Olanzapine in Children and Adolescents With Tourette Syndrome,&quot;<i> J Child Adolesc Psychopharmacol</i>, 2008, 18(5):501-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/18928414/pubmed\" target=\"_blank\" id=\"18928414\">18928414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehler C, Wewetzer C, Schulze U, et al, &quot;Olanzapine in Children and Adolescents With Chronic Anorexia Nervosa. A Study of Five Cases,&quot; <i>Eur Child Adolesc Psychiatry</i>, 2001, 10(2):151-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/11469288/pubmed\" target=\"_blank\" id=\"11469288\">11469288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehler-Wex C, Romanos M, Kirchheiner J, et al, &quot;Atypical Antipsychotics in Severe Anorexia Nervosa in Children and Adolescents - Review and Case Reports,&quot; <i>Eur Eat Disord Rev</i>, 2008, 16(2):100-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/18000964/pubmed\" target=\"_blank\" id=\"18000964\">18000964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health,&quot; Antenatal and Postnatal Mental Health, National Clinical Practice Guideline Number 45,&quot; 2007. Available at http://publications.nice.org.uk/antenatal-and-postnatal-mental-health-cg45</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. Available at https://www.nice.org.uk/guidance/cg155.26065063</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Calamaras MR, DeVane CL, et al, &quot;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&quot; <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17671284/pubmed\" target=\"_blank\" id=\"17671284\">17671284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacchiarotti I, Le&oacute;n-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/27568278/pubmed\" target=\"_blank\" id=\"27568278\">27568278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15949658\"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. <i>JAMA Pediatr</i>. 2015;169(4):e150285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/25844991/pubmed\" target=\"_blank\" id=\"25844991\">25844991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw P, Sporn A, Gogtay N, et al, &quot;Childhood-Onset Schizophrenia: A Double-Blind, Randomized, Clozapine-Olanzapine Comparison,&quot; <i>Arch Gen Psych</i>, 2006, 63(7):721-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/16818861/pubmed\" target=\"_blank\" id=\"16818861\">16818861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sikich L, Frazier JA, McClellan J, et al, &quot;Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study,&quot; <i>Am J Psychiatry</i>, 2008, 165(11):1420-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/18794207/pubmed\" target=\"_blank\" id=\"18794207\">18794207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stachnik JM and Nunn-Thompson C, &quot;Use of Atypical Antipsychotics in the Treatment of Autistic Disorder,&quot; <i>Ann Pharmacother</i>, 2007, 41(4):626-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17389666/pubmed\" target=\"_blank\" id=\"17389666\">17389666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stephens RJ, Bassel C, and Sandor P, &quot;Olanzapine in the Treatment of Aggression and Tics in Children With Tourette's Syndrome - A Pilot Study,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2004, 14(2):255-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/15319022/pubmed\" target=\"_blank\" id=\"15319022\">15319022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tohen M, Kryzhanovskaya L, Carlson G, et al, &quot;Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania,&quot; <i>Am J Psychiatry</i>, 2007, 164(10):1547-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/17898346/pubmed\" target=\"_blank\" id=\"17898346\">17898346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/27028982/pubmed\" target=\"_blank\" id=\"27028982\">27028982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16244481\"></a>Whitworth A, Stuppaeck C, Yazdi K, et al. Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months. <i>J Psychopharmacol</i>. 2010;24(1):121-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/16244481/pubmed\" target=\"_blank\" id=\"16244481\">16244481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wozniak J, Mick E, Waxmonsky J, et al, &quot;Comparison of Open-Label, 8-Week Trials of Olanzapine Monotherapy and Topiramate Augmentation of Olanzapine for the Treatment of Pediatric Bipolar Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(5):539-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-pediatric-drug-information/abstract-text/19877978/pubmed\" target=\"_blank\" id=\"19877978\">19877978</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16033 Version 239.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F46537504\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709177\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26715078\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F203157\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1028249\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1028285\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26715079\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F26730983\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874938\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1028292\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F203151\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1028250\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203206\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203203\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203138\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203120\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26019544\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F203191\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203125\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203127\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2839122\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1028296\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203119\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F203137\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F11408495\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F203140\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F203142\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16033|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine: Drug information</a></li><li><a href=\"topic.htm?path=olanzapine-patient-drug-information\" class=\"drug drug_patient\">Olanzapine: Patient drug information</a></li></ul></div></div>","javascript":null}